December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

36.40 +0.07 (+0.19%)
Official Closing Price Updated: 4:10 PM EDT, Mar 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Could Buying Eli Lilly Today Set You Up for Life? ↗
Eli Lilly is leading the GLP-1 market, and investors are enthralled with the stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
What's Happening With Novo Nordisk Stock Today? ↗
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the... 
Via Benzinga
News headline image
Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
Via MarketMinute
News headline image
Kodiak Sciences Surges 19% as Phase 3 GLOW2 Trial Delivers Vital Win for Diabetic Retinopathy Treatment
On March 26, 2026, Kodiak Sciences (Nasdaq: KOD) saw its shares ignite, surging 19% in heavy trading following the announcement of overwhelmingly positive topline results from its Phase 3 GLOW2 study.... 
Via MarketMinute
News headline image
Surging Oil Prices Spark Market Jitters ↗
The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition
On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash... 
Via Finterra
Topics Initial Public Offering Intellectual Property World Trade
News headline image
Think Novo Nordisk Can't Keep Up in the GLP-1 Market? Its Latest Drug Approval Could Be a Game Changer ↗
The company recently obtained approval for a higher-dose version of Wegovy. 
Via The Motley Fool
News headline image
Institutional Titans Bet Big on Amgen as Dividend Yield Hits 2.9% Benchmark
In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026.... 
Via MarketMinute
Topics ETFs Earnings
News headline image
Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics? ↗
One of these assets is catalyst-driven; the other isn't. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Eli Lilly Stock Before April 10? ↗
A catalyst for stock performance may be just ahead. 
Via The Motley Fool
News headline image
Is This Stock a Buy on the Dip? ↗
This company has a habit of beating the market over long periods. 
Via The Motley Fool
News headline image
This Hims & Hers Move Could Destroy Competitors ↗
The Wegovy pill could change Hims & Hers' growth in 2026. 
Via The Motley Fool
News headline image
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗
The healthcare stock has lost more than half of its value in the past year. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly? ↗
Eli Lilly's GLP-1 drugs are leaders in a new and exciting drug category, but investors already know this fact. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Reason I'm Never Selling Novo Nordisk Stock ↗
I am not turned off by the company's recent setbacks. 
Via The Motley Fool
News headline image
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year... 
Via Finterra
Topics Intellectual Property
News headline image
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗
The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform. 
Via Stocktwits
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Even on a budget, you can get quality stocks. 
Via The Motley Fool
News headline image
Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics ↗
Each of these companies could benefit from this high-growth market over time. 
Via The Motley Fool
News headline image
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗
These companies are benefiting from a tidal wave of demand for new weight-loss drugs. 
Via The Motley Fool
Topics Stocks
News headline image
LLY Shares Dive On Analyst Downgrade Citing Obesity Market Overestimation Concerns, But Retail Dismisses ‘Absurd’ Selloff ↗
The analyst’s new price target represents a potential downside of about 14% from the stock’s last closing price on Monday. 
Via Stocktwits
News headline image
Why Eli Lilly Stock Just Dropped ↗
Eli Lilly's stock price is based on growth rates that might fall short. 
Via The Motley Fool
News headline image
This Promising GLP-1 Drug Could Give Novo Nordisk Investors Renewed Hope for the Stock ↗
Novo Nordisk recently announced promising trial results for one of its GLP-1 drugs in development. 
Via The Motley Fool
News headline image
Should You Avoid Pfizer? Here's the Key Risk to Watch ↗
Pfizer has reached a turning point. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending. 
Via The Motley Fool
News headline image
Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand ↗
Via MarketBeat
MarketBeat Week in Review – 03/09 - 03/13 ↗
Despite continued volatility, stocks have stayed resilient as investors navigate the fog of war. The story is largely about oil. When the price of crude oil goes up, stocks go down and vice versa.... 
Via MarketBeat
News headline image
Is Eli Lilly's Weight Loss Empire in Trouble? ↗
It won't be easy to knock the company off its pedestal. 
Via The Motley Fool
News headline image
3 Dirt-Cheap Stocks to Buy With $1,000 Right Now ↗
As the old adage goes, cheap stocks are cheap for a reason. But the reason might not be a good one. 
Via The Motley Fool
Topics Earnings
News headline image
The Real Reason Eli Lilly Is Pouring $3 Billion Into China ↗
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.